Use access key #2 to skip to page content.

gnulaw (47.20)

Cyanotech (NASDAQ:CYAN): BioAstin vs. CDX-085? That is the question. And other smoking guns?



July 30, 2011 – Comments (1) | RELATED TICKERS: CYAN , BMY , ABT


Cyanotech (NASDAQ:CYAN):  BioAstin vs. CDX-085? That is the question. And other smoking guns?

The July/August 2011 Issue of LifeExtension Magazine has a feature front-cover article on Astaxanthin [1]. (References, bottom of page)

The first two sentences of this article (immediately below) refers to a non-formal public disclosure made by Cyanotech and published April 05 by NUTRA, five days after Cyanotech's q4/fy 2011 ending March 31, 2011. Note that this was not included nor as a "Subsequent Event" in CYANs recently filed SEC Form 10-K for its Fiscal year ended March 31, 2011 and signed by its Chairman, President, and Senior Officers on June 23, 2011.  Further note that as of of this writing, July 30, 2011 and AS A MATTER OF RECORD neither the Cyanotech Board of Directors nor its Senior Officers have announced a release date for Q1 2012 numbers ending June 30, 2011.


"...Earlier this year, celebrity physician Dr. Oz touted a compound vital to preserving visual acuity in maturing individuals. He called it “The #1 Supplement You’ve Never Heard of That You Should Be Taking.”1..."

1. Available at: Accessed April 8, 2011.


The LifeExtension article also contains a sidebar article entitled: ASTAXANTHIN AND DRUG COMPANY PROFITEERING


"...The emerging body of research supporting astaxanthin’s broad-spectrum benefits has not escaped Big Pharma’s notice. As of this writing, efforts are underway to develop patentable synthetic versions of astaxanthin to treat various forms of cardiovascular disease.4-8 The best known of these, Cardax, provides yet another example of the drug industry’s corrupt, cynical maneuvering to put profits over the public health. Cardax (disodium disuccinate astaxanthin) is simply a “pro-drug,” an inactive parent molecule that disintegrates into astaxanthin following ingestion.9 In other words, drug makers hope to charge a premium for an inactive form of a natural, safe, low-cost nutrient, and then let patients’ bodies act on the drug to convert it back into that same nutrient..." [Emphasis added]

Who is Cardax Pharmaceuticals?

"...Cardax Pharmaceuticals is developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play important causative roles. The Company’s platform includes CDX-085 with application in metabolic syndrome, arthritis, and cardiovascular disease, as well as other proprietary prodrugs for macular degeneration and prostate disease...".

Our Drugs vs Dietary Supplements

"...Our drugs are proprietary modifications (or “prodrugs”) of powerful anti-oxidant/anti-inflammatory xanthophyll carotenoid compounds, usually found in esterified form in nature, that have evolved over millions of years. Like astaxanthin dietary supplements made from extracts of the microalgae Haematococcus Pluvialis, CDX-085 is comprised of astaxanthin esters but in a far purer form (>90% vs. 5%-16%). Despite the increased purity, however, CDX-085 costs substantially less than dietary supplements per mg of astaxanthin to produce and its production is cleaner and more sanitary.

Importantly, unlike dietary supplements, our drugs will go through the rigorous FDA process to prove safety and efficacy in human clinical trials with manufacturing purity/control, thereby providing doctors and patients with the assurance of the consistency, efficacy, and safety of an FDA approved drug.." [Emphasis added].

Cardax - Important U.S. Patents

The question is, how does Cardax Pharmaceuticals affect CYANs Astaxanthin pipeline and professed competitive advantages CYAN has significantly failed to translate into shareholder value, to date?

Other smoking guns:

Cyanotech's BioAstin Marketing website confirms this management team has no clue and is controlled by a out of touch family-run business mindset.

1.  BioAstin Brand logo is tragically and incomprehensibly unprofessional and embarrassing and simply symptomatic of the above.

2.  Confusion between Cyanotech, Nutrex, MDFormulas brands.

3.  Nutrex-Hawaii needs a twitter button along with Facebook...but that's the least of the CYAN non-insider shareholders' problems.

Cyanotech (NASDAQ:CYAN) simply is not tight, from its transparency in producing timely numbers/conference calls to its shallow management team, which simply lacks bandwidth. The failure in management in creating and maintaining shareholder value over the past twenty years and especially, in light of unanimous astaxanthin claims, poignantly and conclusively confirms this.


1. (July/August) LifeExtension Magazine. BEYOND EYE HEALTH  How Astaxanthin Combats Degenerative Disease.

2.  (July 03, 2011) Cyanotech (NASDAQ:CYAN) Update . Non-insider shareholder(s) urge for an acquisition citing failure(s) of current management and Board of Directors.

3.  (April 15, 2011) (NASDAQ:CYAN) Pending Breakout and or Acquisition? The Little Engine That Could.


1 Comments – Post Your Own

#1) On August 05, 2011 at 11:22 AM, gnulaw (47.20) wrote:

AS A MATTER OF RECORD as of August 05 2011 neither the Cyanotech Board of Directors nor its Senior Officers have announced a release date for Q1 2012 numbers ending June 30, 2011.

Report this comment

Featured Broker Partners